Precision medicine is defined as an approach to personalized diagnosis and treatment, based on the omics information of patients. Human cancer is a complex and intrinsically heterogeneous disease in which patients may exhibit similar symptoms, and appear to have the same pathological disease, for entirely different genetic reasons. Such heterogeneity results in dramatic variations in response to currently available anti-cancer drugs. Therefore, oncology is one of the best fields for the practice of precision medicine. The availability of omics-based big data, along with rapid development of biotechnology, paves a way for precision medicine. This article describes the concept, foundation and significance of precision medicine, and reviews the recent progresses in methodology development and their clinical application. Then, various current available biotechniques in precision medicine are evaluated and classified into indirect (biomarker-based detection and prediction) and direct (patient-derived cells and tissues for direct anti-cancer drug screening) categories. Finally, perspectives of precision medicine as well as its facing challenge are briefly discussed.
HANG Bo
,
SHU Yongqian
,
LIU Ping
,
WEI Guangwei
,
JIN Jian
,
HAO Wenshan
,
WANG Peijun
,
LI Bin
,
MAO Jianhua
. Precision cancer medicine: Concept, technology and perspectives[J]. Science & Technology Review, 2015
, 33(15)
: 14
-21
.
DOI: 10.3981/j.issn.1000-7857.2015.15.001
[1] National Research Council: Committee on a Framework for Developing a New Taxonomy of Disease. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease [R]. Washington D C: National Academies Press, 2011.
[2] Collins F S, Varmus H. A new initiative on precision medicine[J]. New England Journal of Medicine, 2015, 372(9): 793-795.
[3] Reardon S. Precision-medicine plan raises hopes[J]. Nature, 2015, 517 (7536): 540.
[4] Lander E S, Linton L M, Birren B, et al. Initial sequencing and analysis of the human genome[J]. Nature, 2001, 409(6822): 860-921.
[5] Venter J C, Adams M D, Myers E W, et al. The sequence of the human genome[J]. Science, 2001, 291(5507): 1304-1351.
[6] Mao J H, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: Frequent deletion or downregulation of Aurora- A in tumors from p53 null mice[J]. Cancer Cell, 2007, 11(2): 161-173.
[7] Mao J H, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene[J]. Nature, 2004, 432(7018): 775-779.
[8] Mao J H, Wu D, Kim I J, et al. Hipk2 cooperates with p53 to suppress γ- ray radiation-induced mouse thymiclymphoma[J]. Oncogene, 2012, 31(9): 1176-1180.
[9] Mao J H, Wu D, Perez-Losada J, et al. Genetic interactions between Pten and p53 in radiation- induced lymphoma development[J]. Oncogene, 2003, 22(52): 8379-8385.
[10] Lovly C M, McDonald N T, Chen H, et al. Rationale for co-targeting IGF- 1R and ALK in ALKfusion- positive lung cancer[J]. Nature Medicine, 2014, 20(9): 1027-1034.
[11] U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development[R]. 2013 Oct.
[12] Mao J H, Kim I J, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression[J]. Science, 2008, 321 (5895): 1499-1502.
[13] Villaruz L C, Socinski M A. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7mutation[J]. Lung Cancer, 2014, 83(2): 300-301.
[14] Geiss G K, Bumgarner R E, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs[J]. Nature Biotechnology, 2008, 26(3): 317-325.
[15] Crystal A S, Shaw A T, Sequist L V, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J]. Science, 2014, 346(6216): 1480-1486.
[16] Grivel J C, Margolis L. Use of human tissue explants to study human infectious agents[J]. Nature Protocols, 2009, 4(2): 256-269.
[17] Couzin-Frankel J. Hope in a mouse[J]. Science, 2014, 346(6205): 28-29.
[18] Lancaster M A, Knoblich J A. Organogenesis in a dish: Modeling development and disease using ornaoidtechniques[J]. Science, 2014, 345 (6194): 283-292.
[19] Nelson C M, Vanduijn M M, Inman J L, et al. Tissue geometry determines sites of mammary branching morphogenesis in organotypiccultures[J]. Science, 2006, 314(5797): 298-300.
[20] Yu M, Bardia A, Aceto N, et al. Cancer therapy- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J]. Science, 2014, 345(6193): 216-220.
[21] Celli J P, Rizvi I, BlandenA R, et al. An imaging-based platform for high- content, quantitative evaluation of therapeutic response in 3D tumourmodels[J]. Scientific Reports, 2014, 4(3751): 1-10.
